Sheela N Magge1, Babette S Zemel2,3, Mary E Pipan3,4, Samuel S Gidding5, Andrea Kelly3,6. 1. Division of Endocrinology and Diabetes, School of Medicine and Health Sciences, The George Washington University and Clinical and Translational Science Institute at Children's National, Children's Research Institute, Children's National Health System, Washington, District of Columbia; Divisions of smagge3@jhmi.edu. 2. Gastroenterology, Hepatology, and Nutrition. 3. Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania; and. 4. Developmental Behavioral Pediatrics, and. 5. Familial Hypercholesterolemia Foundation, Pasadena, California. 6. Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Abstract
BACKGROUND AND OBJECTIVES: Whether BMI captures adiposity and cardiometabolic risk in Down syndrome (DS), a condition associated with obesity, short stature, and altered body proportions, is not known. We compared cardiometabolic risk measures in youth with DS and typically developing matched controls. METHODS: Youth with (n = 150) and without (n = 103) DS of comparable age (10-20 years), sex, race, ethnicity, and BMI percentile underwent whole-body dual-energy X-ray absorptiometry, fasting glucose, insulin, lipids, lipoprotein particles, inflammatory factors, and when BMI percentile ≥85, an oral glucose tolerance test. RESULTS: Sixty-four percent of youth with DS had BMI percentile ≥85. Among these, no difference in glucose, insulin, or insulin resistance was detected, but prediabetes was more prevalent with DS (26.4% vs 10.3%; P = .025) after adjustment for demographics, pubertal status, and BMI z score (odds ratio = 3.2; P = .026). Among all participants, those with DS had higher low-density lipoprotein cholesterol (median 107 [interquartile range 89-128] vs 88.5 [79-103] mg/dL; P < .00005), triglycerides (89.5 [73-133] vs 71.5 [56-104] mg/dL; P < .00005), non-high-density lipoprotein cholesterol (non-HDL-C; 128 [104-153] vs 107 [92-123] mg/dL; P < .00005), and triglycerides/HDL-C (2.2 [1.6-3.4] vs 1.7 [1.1-2.5] mg/dL; P = .0003) and lower levels of HDL-C (41 [36.5-47] vs 45 [37-53] mg/dL; P = .012). DS youth had higher high-sensitivity C-reactive protein, interleukin-6, small low-density lipoprotein particles (LDL-P), and total LDL-P, but similar LDL-P size. Youth with DS had less visceral fat (VFAT), fat mass, and lean mass for BMI z score, but greater VFAT at higher fat mass. However, VFAT did not fully explain the increased prevalence of dyslipidemia or prediabetes in youth with DS. CONCLUSIONS: Despite similar insulin resistance, youth with DS had greater prevalence of dyslipidemia and prediabetes than typically developing youth, which was not fully explained by VFAT.
BACKGROUND AND OBJECTIVES: Whether BMI captures adiposity and cardiometabolic risk in Down syndrome (DS), a condition associated with obesity, short stature, and altered body proportions, is not known. We compared cardiometabolic risk measures in youth with DS and typically developing matched controls. METHODS: Youth with (n = 150) and without (n = 103) DS of comparable age (10-20 years), sex, race, ethnicity, and BMI percentile underwent whole-body dual-energy X-ray absorptiometry, fasting glucose, insulin, lipids, lipoprotein particles, inflammatory factors, and when BMI percentile ≥85, an oral glucose tolerance test. RESULTS: Sixty-four percent of youth with DS had BMI percentile ≥85. Among these, no difference in glucose, insulin, or insulin resistance was detected, but prediabetes was more prevalent with DS (26.4% vs 10.3%; P = .025) after adjustment for demographics, pubertal status, and BMI z score (odds ratio = 3.2; P = .026). Among all participants, those with DS had higher low-density lipoprotein cholesterol (median 107 [interquartile range 89-128] vs 88.5 [79-103] mg/dL; P < .00005), triglycerides (89.5 [73-133] vs 71.5 [56-104] mg/dL; P < .00005), non-high-density lipoprotein cholesterol (non-HDL-C; 128 [104-153] vs 107 [92-123] mg/dL; P < .00005), and triglycerides/HDL-C (2.2 [1.6-3.4] vs 1.7 [1.1-2.5] mg/dL; P = .0003) and lower levels of HDL-C (41 [36.5-47] vs 45 [37-53] mg/dL; P = .012). DS youth had higher high-sensitivity C-reactive protein, interleukin-6, small low-density lipoprotein particles (LDL-P), and total LDL-P, but similar LDL-P size. Youth with DS had less visceral fat (VFAT), fat mass, and lean mass for BMI z score, but greater VFAT at higher fat mass. However, VFAT did not fully explain the increased prevalence of dyslipidemia or prediabetes in youth with DS. CONCLUSIONS: Despite similar insulin resistance, youth with DS had greater prevalence of dyslipidemia and prediabetes than typically developing youth, which was not fully explained by VFAT.
Authors: Nicolai M Doliba; Wei Qin; Habiba Najafi; Chengyang Liu; Carol W Buettger; Johanna Sotiris; Heather W Collins; Changhong Li; Charles A Stanley; David F Wilson; Joseph Grimsby; Ramakanth Sarabu; Ali Naji; Franz M Matschinsky Journal: Am J Physiol Endocrinol Metab Date: 2011-09-27 Impact factor: 4.310
Authors: Courtney M Peterson; Haiyan Su; Diana M Thomas; Moonseong Heo; Amir H Golnabi; Angelo Pietrobelli; Steven B Heymsfield Journal: JAMA Pediatr Date: 2017-07-01 Impact factor: 16.193
Authors: Vera Bittner; Regina Hardison; Sheryl F Kelsey; Bonnie H Weiner; Alice K Jacobs; George Sopko Journal: Circulation Date: 2002-11-12 Impact factor: 29.690
Authors: Hillary Dolan; Barbara Crain; Juan Troncoso; Susan M Resnick; Alan B Zonderman; Richard J Obrien Journal: Ann Neurol Date: 2010-08 Impact factor: 10.422
Authors: Deirdre A Hill; Gloria Gridley; Sven Cnattingius; Lene Mellemkjaer; Martha Linet; Hans-Olof Adami; Jorgen H Olsen; Olof Nyren; Joseph F Fraumeni Journal: Arch Intern Med Date: 2003-03-24
Authors: Weiquan Lu; Helaine E Resnick; Kathleen A Jablonski; Kristina L Jones; Arvind K Jain; Wm James Howard; David C Robbins; Barbara V Howard Journal: Diabetes Care Date: 2003-01 Impact factor: 19.112
Authors: Anabel N Rodrigues; Luan Cesar Coelho; Washington L S Goncalves; Sonia Alves Gouvea; Maria José Rossi Vasconcellos; Roberto S Cunha; Glaucia R Abreu Journal: Vasc Health Risk Manag Date: 2011-06-09
Authors: Stephanie T Chung; Samantha T Matta; Abby G Meyers; Celeste K Cravalho; Alfredo Villalobos-Perez; Joshua M Dawson; Vandhna R Sharma; Maureen L Sampson; James D Otvos; Sheela N Magge Journal: Front Endocrinol (Lausanne) Date: 2021-05-18 Impact factor: 5.555
Authors: Geiziane Leite Rodrigues Melo; Ivo Vieira de Sousa Neto; Eduardo Fernandes da Fonseca; Whitley Stone; Dahan da Cunha Nascimento Journal: Front Physiol Date: 2022-09-27 Impact factor: 4.755
Authors: James A Hendrix; Angelika Amon; Leonard Abbeduto; Stamatis Agiovlasitis; Tarek Alsaied; Heather A Anderson; Lisa J Bain; Nicole Baumer; Anita Bhattacharyya; Dusan Bogunovic; Kelly N Botteron; George Capone; Priya Chandan; Isabelle Chase; Brian Chicoine; Cécile Cieuta-Walti; Lara R DeRuisseau; Sophie Durand; Anna Esbensen; Juan Fortea; Sandra Giménez; Ann-Charlotte Granholm; Laura J Hahn; Elizabeth Head; Hampus Hillerstrom; Lisa M Jacola; Matthew P Janicki; Joan M Jasien; Angela R Kamer; Raymond D Kent; Bernard Khor; Jeanne B Lawrence; Catherine Lemonnier; Amy Feldman Lewanda; William Mobley; Paul E Moore; Linda Pollak Nelson; Nicolas M Oreskovic; Ricardo S Osorio; David Patterson; Sonja A Rasmussen; Roger H Reeves; Nancy Roizen; Stephanie Santoro; Stephanie L Sherman; Nasreen Talib; Ignacio E Tapia; Kyle M Walsh; Steven F Warren; A Nicole White; Guang William Wong; John S Yi Journal: Transl Sci Rare Dis Date: 2021-04-15